CN102860509A - Anti-fatigue immunity-improving health food and preparation method thereof - Google Patents
Anti-fatigue immunity-improving health food and preparation method thereof Download PDFInfo
- Publication number
- CN102860509A CN102860509A CN2012103797045A CN201210379704A CN102860509A CN 102860509 A CN102860509 A CN 102860509A CN 2012103797045 A CN2012103797045 A CN 2012103797045A CN 201210379704 A CN201210379704 A CN 201210379704A CN 102860509 A CN102860509 A CN 102860509A
- Authority
- CN
- China
- Prior art keywords
- health food
- mouse
- immunity
- present
- fatigue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses anti-fatigue immunity-improving health food. The anti-fatigue immunity-improving health food comprises, by weight percent, 20-40% of astragali root, 20-40% of rehmannia root, 5-25% of red-rooted salvia root, 5-20% of wolfberry fruit, and 5-15% of Chinese caterpillar fungus. The invention further discloses a preparation method of the health food. The anti-fatigue immunity-improving health food made of the natural traditional Chinese medicines functions in improving immunity and resisting fatigue, causes no side effects, and is suitable for people of all ages. In addition, the preparation method is simple and causes no change in properties of the materials, and the anti-fatigue immunity-improving health food can be kept for a long period of time.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of health food with raising immunity, antifatigue effect and preparation method thereof.
Background technology
Immunity is the defense mechanism of human body self, be human body identification and any foreign matter (virus, bacterium etc.) of eliminating external intrusion, process the ability of self cell and identification and processing vivo mutations cell and the virus infected cell of old and feeble, damage, death, sex change.Immune dysfunction or when low can reduce body to anti-infectious ability, reduces identification and removes the histocyte ability of self aging, reduces and kills and wounds and remove abnormal sudden change cell ability in vivo, causes the decline of human body premunition and vis medicatrix naturae.And modern society, the quickening of rhythm of life, the increase of competitive pressure, every day, the working and learning meeting of anxiety made body be in the overdraw state, as can not get having a rest timely and adjusting, and accumulated over a long period, will the Immunosuppression function; Simultaneously, nervous working and learning allow the more people instant fast food of having to, and cause the unbalance of endotrophic element, if body is in this state for a long time, immunity of organisms are descended, and finally cause the sub-health state of body.
Tired as a kind of physiological phenomenon, is a kind of mechanism of protectiveness to the people, be that health sends the signal that have a rest to us, if to it no matter ignore, health will suffer damage.The develop rapidly of science and technology is so that the household electrical appliances such as mobile phone, TV, computer, fluorescent lamp, micro-wave oven, electromagnetic oven, air-conditioning, hair-dryer, dust catcher become the necessary articles for use of every household, these household electrical appliances are when bringing convenience to people, also so that people be in the encirclement of electromagnetic radiation, be in for a long time in the environment of electromagnetic radiation, can make the people have in various degree feel headache, dizzy, feel sick, the fatigue symptom such as tinnitus, eyes are dry and astringent.
Therefore, take in to improve immunity health food and fatigue resistant health food and be sought after, certainly, not only had the health food that improves immunity but also antifatigue effect is arranged then more practical if can provide a kind of.
Summary of the invention
Goal of the invention: the object of the invention is to for the deficiencies in the prior art, a kind of health food that improves immunity, antifatigue effect that has is provided.
Another object of the present invention is to provide the preparation method of above-mentioned health food.
Technical scheme: in order to reach the foregoing invention purpose, the present invention specifically is achieved like this: a kind of have a health food that improves immunity, antifatigue effect, is comprised of the component of following percentage by weight: 20 ~ 40% the Radix Astragali, 20 ~ 40% glutinous rehmannia, 5 ~ 25% the red sage root, 5 ~ 20% the fruit of Chinese wolfberry and 5 ~ 15% Cordyceps sinensis.
Wherein, the preferred natural cordyceps of described Cordyceps sinensis, paecilomycerol bat moth mycelium or Hirsutella sinensis mycelium.
Wherein, the formulation of described health food can adopt capsule, pulvis, soft capsule, tablet or oral liquid.
Prepare above-mentioned method with the health food that improves immunity, antifatigue effect, may further comprise the steps:
(1) measures each raw material by prescription, pulverize, cross 80 mesh sieves;
(2) each raw material after will sieving mixes, and is prepared into capsule, pulvis, soft capsule or tablet.
Beneficial effect: it is raw material that the present invention adopts natural traditional Chinese medicine, when reaching raising immunity, antifatigue effect, can not have side effects, and is fit to all age group crowd; Simultaneously, preparation method of the present invention is simple, can not cause the variation of each feedstock property, can long preservation.
The specific embodiment
Embodiment 1:
Get the Radix Astragali, 20% glutinous rehmannia, 5% Cordyceps sinensis, 20% the red sage root and 15% the fruit of Chinese wolfberry of percetage by weight 40%, pulverized 80 mesh sieves, the capsule of the 400mg that packs into.
Embodiment 2:
Get the Radix Astragali, 25% glutinous rehmannia, 10% Cordyceps sinensis, 25% the red sage root and 10% the fruit of Chinese wolfberry of percetage by weight 30%, pulverized 80 mesh sieves, make the pulvis pack of 1g.
Embodiment 3:
Get the Radix Astragali, 30% glutinous rehmannia, 10% Cordyceps sinensis, 5% the red sage root and 20% the fruit of Chinese wolfberry of percetage by weight 35%, pulverized 80 mesh sieves, compressing tablet becomes the tablet of 500mg.
Embodiment 4:
Get the Radix Astragali, 35% glutinous rehmannia, 15% Cordyceps sinensis, 15% the red sage root and 15% the fruit of Chinese wolfberry of percetage by weight 20%, pulverized 80 mesh sieves, the soft capsule of the 400mg that packs into.
Embodiment 5:
Get the Radix Astragali, 40% glutinous rehmannia, 10% Cordyceps sinensis, 20% the red sage root and 5% the fruit of Chinese wolfberry of percetage by weight 25%, pulverized 80 mesh sieves, add the oral liquid that 10 times of distilled water of raw material volume are made every of 10ml.
Embodiment 6:
The present invention improves the immunity function experimental study
1. material
1.1 sample: provided by S﹠P Pharmaceutical Co., Ltd..
1.2 animal used as test
160 of Kunming mouses, entirely female, body weight 18-22g.
2. experimental technique
2.1 dosage is selected
Tested material is established 400mg/kg.BW, 800mg/kg.BW, three dosage groups of 1200 mg/kg.BW (be equivalent to respectively human body recommended intake 10 times, 20 times, 30 times), take by weighing respectively 10.00g, 20.00g, 30.00g tested material adding distil water to the 250ml mixing, stored refrigerated, be finished again and join, other establishes the edible vegetable oil negative control group, every group of 40 animals.Be divided into immune one group, two groups, three groups, four groups, wherein one group is used for Turnover of Mouse Peritoneal Macrophages and engulfs the chicken red blood cell experiment; Two groups are used for NK cytoactive detection and lymphocyte transformation experiment; Three groups are used for antibody-producting cell experiment, serum hemolysin mensuration and delayed allergy; Four groups are used for mouse carbon and clean up experiment.Mouse gives 30 days continuously by per os gavage of 10 mg/kg.BW body weight, claims weekly body weight one time, adjusts the gavage volume.
2.2 experimental procedure
2.2.1 mouse carbon clearance test: gavage is after 30 days continuously, in the india ink of mouse tail vein injection with 4 times of normal saline dilutions, immediately timing after pressing 0.1ml/10g prepared Chinese ink and injecting is after injecting prepared Chinese ink the 2nd, 10min gets blood 20 μ l from the angular vein clump respectively, is added to 2mlNa
2CO
3In the solution, with Na
2CO
3Solution is made blank, measures OD value at the 600nm place with 723 spectrophotometers.Put to death mouse after getting blood, get liver, spleen is weighed, calculate phagocytic index.
2.2.2 Turnover of Mouse Peritoneal Macrophages is engulfed chicken red blood cell experiment (half intracorporal method): gavage is after 30 days continuously, the chicken erythrocyte suspension 1ml of every mouse peritoneal injection 20%, after 30 minutes, the cervical vertebra dislocation is put to death, be fixed on the mouse plate, abdominal skin is cut off in the center, through Intraperitoneal injection physiological saline 2ml, rotated the mouse plate 1 minute, sucking-off abdominal cavity washing lotion 1ml, mean droplet is on 2 slides, put 37 ℃ in wet box 30 minutes, and took out in the physiological saline rinsing, dry, fixing, 4%GiemsaPBS dyeing 3 minutes, the distilled water rinsing is dried, microscopy.Calculate phagocytic percentage and phagocytic index.
2.2.3 delayed allergy (DTH) (the sufficient sole of the foot thickens method): gavage is after 30 days, inject the every mouse of 2% hematocrit SRBC(0.2ml/ to mouse peritoneal) sensitization is after 4 days, measure left back sufficient sole of the foot thickness, and then measuring point hypodermic injection 20%(v/v) the every mouse of SRBC(20 μ l/), 24h measures left back sufficient sole of the foot thickness after injection, same position is measured three times, averages, and represents the degree of DTH with sufficient sole of the foot thickness difference (swelling degree of the paw) before and after attacking.
2.2.4ConA the mouse lymphocyte conversion test (mtt assay) of inducing: at first carry out the preparation of splenocyte suspension.Cell concentration is adjusted into 3 * 10
6Individual/ml, then cell suspension is divided two holes to add in 24 well culture plates, every hole 1ml, a hole adds 75 μ lConA liquid, and another hole compares, and puts 5%CO
237 ℃ of cultivations of incubator 72h.Cultivate and finish front 4h, every hole sucks gently supernatant 0.7ml and adds the RPMI1640 nutrient solution that 0.7ml does not contain calf serum, add simultaneously MTT (5mg/ml) 50 μ l/ holes and continue to cultivate 4h, after cultivating end, every hole adds 1ml acid isopropyl alcohol, purple crystal is dissolved fully, then every hole liquid is moved in the cuvette, with 723 spectrophotometers in 570nm wavelength place's colorimetric estimation OD value.
2.2.5 antibody-producting cell detects (Jernr improves slide method): gavage is after 30 days continuously, every mouse peritoneal is injected 2% hematocrit SRBC0.2ml, the mouse cervical vertebra dislocation of immunity after 5 days half put to death, take out spleen and be placed in the plate that fills Hank ' s liquid, make splenocyte suspension.Agarose is made into 1% aqueous solution, and 30min is boiled in water-bath, mix with the double Hank ' s of equivalent liquid, and the packing small test tube, every pipe 0.5ml adds 10%(S again in pipe
AThe buffer solution preparation) hematocrit SRBC50 μ l, each 20 μ l of splenocyte suspension do two Duplicate Samples, rapidly behind the mixing, be poured on the agarose thin layer slide, after agar solidifies, the slide level buckled be placed on the horse, put into CO2gas incubator and hatch 1.5h, then complement is joined in the slide frame groove, continue incubation 1.5h, counting hemolysis plaque number.
2.2.6 serum hemolysin is measured (Hemagglutination Method): in continuous gavage after 30 days, every mouse peritoneal injection 2%SRBC0.2ml immunity, continue gavage after 5 days, extract eyeball and get blood in centrifuge tube, place 1h, peel off, the centrifugal 10min of 2000r/min collects serum, with physiological saline serum is made doubling dilution, every part of dilution 12 holes place blood-coagulation-board with the dilution serum of difference, every hole 100 μ l, add again 0.5%SRBC suspension 100 μ l, mixing is put observed result behind wet 37 ℃ of 3h of box, records the aggegation degree in every hole.The calculating antibody product.
2.2.7NK cytoactive detection (lactate dehydrogenase L DH determination method): continuously gavage is after 30 days, and animal is put to death in the cervical vertebra dislocation, takes out spleen, tears up, cross 200 eye mesh screens after, use Hank ' s liquid to wash 3 times, be made into 2 * 10 with complete RPMI1640 nutrient solution
7Individual/the ml cell suspension.The cell suspension of each mouse is got 300 μ l divide 3 holes to place 96 well culture plates, every hole 100 μ l, every hole adds target cell (YAC-1 cell, 4 * 10
5Individual/ml) 100 μ l, do simultaneously each 8 hole of target cell Spontaneous release hole (target cell 100 μ l+ nutrient solutions 100 μ l) and maximum release aperture (target cell 100 μ l+2.5%Triton100 μ l), 37 ℃ of 5%CO
2Cultivated 4 hours, and took out the centrifugal 5min of 1500r/min.Each hole supernatant 100 μ l is placed another culture plate, and every hole adds 100 μ l matrix liquid again, adds the HCL30 μ l cessation reaction of 1mol/L after 10 minutes, measures the OD value at the 490nm place, calculates NK cytoactive rate.
3. test data is added up
Test data adopts SPSS10.0 for Windows software kit to process.The data of control group and dosage group are through the variance test of homogeneity, and variance is neat, carry out variance analysis,, then compare in twos with the Dunnett method less than 0.05 such as the P value; If heterogeneity of variance then carries out data transaction, and is still uneven, use rank test instead, less than 0.05, then use Dunnett ' sT3 method to compare in twos (P〉0.05 for non-significant difference, P＜0.05 is significant difference) such as the P value.
4. result
4.1 the present invention sees Table 1-4 to the impact of Mouse Weight.
Table 1 respectively organize mouse initial body weight (
± S)
Table 2 respectively organize mouse the body weight in mid-term (
± S)
Table 3 respectively organize mouse the end body weight (
± S)
The impact that table 4 the present invention increases weight on Mouse Weight (
± S)
By table 1-4 as seen, the initial body weight of one group, immune two groups of the present invention immunity, immune three groups and immune four groups of mouse is compared with negative control group, through the variance test of homogeneity, variance neat (P〉0.05), and the results of analysis of variance (P〉0.05), illustrate that the initial body weight of respectively organizing between mouse and the negative control group is balanced.Three dosage group mouse test mid-terms, the body weight in latter stage and the growths of duration of test Mouse Weight are compared with negative control group, learn by statistics and process, there was no significant difference (P〉0.05), i.e. the present invention on the body weight gain of mouse without impact.
4.2 the present invention is on the impact of mouse monokaryon-macrophage phagocytic function
Table 5 the present invention on mouse monokaryon-macrophage carbon clean up function impact (
± S)
By as seen from Table 5, gavage is after 30 days continuously, and the carbon of three dosage group mouse is cleaned up ability and compared with negative control group, and learn by statistics and process, there was no significant difference (P〉0.05).
Table 6 the present invention on mouse macrophage engulf the chicken red blood cell ability impact (
± S)
By as seen from Table 6, gavage is after 30 days continuously, and the phagocytic rate of three dosage treated animals is compared with negative control group with phagocytic index, learns by statistics and processes, and middle and high dosage group phagocytic index has significant difference (P＜0.05).
By table 5, as seen from Table 6, the present invention is positive to mouse monokaryon-macrophage phagocytic function test result.
4.3 the present invention is on the impact of mouse cell immunity
Table 7 the present invention on the impact of mouse delayed allergy (DTH) (
± S)
By as seen from Table 7, gavage is after 30 days continuously, and the swelling degree of the paw of three dosage group mouse is compared with negative control group, and learn by statistics and process, there was no significant difference (P〉0.05)
The impact of the mouse lymphocyte conversion test that table 8 the present invention induces ConA (
± S)
By as seen from Table 8, the gavage mouse is after 30 days continuously, and the lymphopoiesis ability of three dosage group mouse is compared with negative control, and learn by statistics and process, there was no significant difference (P〉0.05).
By table 7, the present invention is negative to mouse cell immunity test result as seen from Table 8.
4.4 the present invention is on the impact of mouse humoral immune
Table 9 the present invention on the impact of mouse antibodies cellulation (
± S)
By as seen from Table 9, gavage is after 30 days continuously, and the hemolysis plaque number of three dosage group mouse is compared with negative control, learns by statistics and processes, and low, middle dosage group has significant difference (P＜0.05).
Table 10 the present invention on the impact of mice serum hemolysin (
± S)
By as seen from Table 10, gavage is after 30 days continuously, and the antibody product of three dosage group mouse is compared with negative control group, learns by statistics and processes, and low dose group has utmost point significant difference (P＜0.05)
By table 9, as seen from Table 10, the present invention is positive to the mouse humoral immune result of the test.
4.5 the present invention is on the impact of NK cells in mice activity
Table 11 the present invention on the impact of NK cells in mice activity (
± S)
By as seen from Table 11, gavage is after 30 days continuously, and three dosage group NK cells in mice activity are compared with negative control, and learn by statistics and process, there was no significant difference (P〉0.05).The present invention is aobvious negative to the NK cytoactive result of the test of mouse.
5. sum up
The continuous gavage mouse of the present invention had no significant effect Mouse Weight after 30 days; Test for celluar immunity result to mouse is negative; NK test cell line result to mouse is negative; To the test for humoral immunity of mouse, the hemolysis plaque number of three dosage groups and negative control group compare, and low, middle dosage group difference all has conspicuousness (P＜0.05), and result of the test is positive; To the monocytes/macrophages phagocytic function test of mouse, the phagocytic rate of three dosage group mouse and phagocytic index and negative control group compare, and middle and high dosage group difference has conspicuousness (P＜0.05), and result of the test is positive.
Can judge according to " health food check and assessment technique standard " version in 2003, the present invention has the function that improves immunity to animal.
Embodiment 7:
The present invention is to the research of alleviating physical fatigue function
1. material
1.1 sample: provided by S﹠P Pharmaceutical Co., Ltd., the human body recommended amounts was 0.45 * 4/ people/day (30mg/kg.bw).
1.2 animal used as test and raising
SPF level male ICR mouse, body weight 19 ~ 22g provides (the animal quality certification number: the SCXK(river) 2004-16 number) by People's Hospital, Sichuan Prov. of Sichuan Academy of Medical Sciences institute of lab animals.Raising condition: barrier level Animal House (Sichuan Province's management of laboratory animal committee credit number: the SYXK(river) 2008-011).
1.3 key instrument
SBA-bio-sensing analyzer, Olympus AU400 type automatic biochemistry analyzer, VIS-7200 visible spectrophotometer, refiner, centrifuge, electronic balance.Above equipment is provided by West China Institute of Analysis of HSPH of Sichuan University.
2. experimental technique
2.1 dosage is selected
Animal used as test is divided into blank group and 3 test group of the present invention at random.Tested material dosage is respectively 300mg/kg.bw, 600 mg/kg.bw, 900 mg/kg.bw(and is equivalent to respectively 10,20 and 30 times of human body recommended intake).Gavage liquid preparation: take by weighing 0.6g, 1.2g and 1.8g sample of the present invention, be dissolved in respectively in the 40ml distilled water, by 20 mg/kg.bw gavages.The blank treated animal is with the distilled water gavage, and each experimental group animal is with the distilled water solution gavage of corresponding dosage, and once a day, gavage was tested after 30 days continuously
2.2 experimental procedure
2.2.1 swimming with a load attached to the body experiment: after last gives tested material 30min, the load mouse of 5% body weight sheet lead of afterbody is placed the swimming trunk went swimming.Many and the 30cm of the depth of water in the case, 25 ± 1 ℃ of water temperatures, mouse begins to Post-dead duration from swimming record.
2.2.2 blood Plasma lactate: after last gave tested material 30min, it was not swimming with a load attached to the body 10min in 30 ℃ the water that animal is put temperature, and before swimming, after the swimming immediately, rest 20min respectively adopts eyeball blood 20 μ L mensuration lactic acid content after the swimming.And by following formula calculating blood lactic acid TG-AUC, to judge the rear blood lactic acid situation of change of motion.Blood lactic acid TG-AUC=5 * (rest 20min blood Lactate after 0min blood Lactate+2 after blood Lactate before the swimming+3 * swimming * swimming)
2.2.3 serum urea nitrogen determination: after last gives tested material 30min, it is not swimming with a load attached to the body 90min in 30 ℃ the water that mouse is put temperature, adopt eyeball blood 0.5mL behind the rest 60min, get serum after the blood clotting and measure the serum urea nitrogen content with Olympus AU400 type automatic biochemistry analyzer.
2.2.4 hepatic glycogen is measured: give tested material 30min in last and put to death animal, get liver and after the physiological saline rinsing, blot with filter paper, take by weighing rapidly liver 100mg, measure hepatic glycogen content (anthrone method).
3. experimental data is added up
Experimental data is carried out variance analysis with PEMS for Windows3.0 statistical package; The heterogeneity of variance data are carried out suitable variable conversion; If do not reach yet the neat person of variance after the variable conversion, add up with rank test.
4 results
4.1 the present invention is on the impact of Mouse Weight
Table 12 the present invention on the impact (swimming with a load attached to the body experiment) of Mouse Weight (
± S)
Table 13 the present invention on the impact (blood Plasma lactate) of Mouse Weight (
± S)
Table 14 the present invention on the impact (determination of urea nitrogen) of Mouse Weight (
± S)
Table 15 the present invention on the impact (hepatic glycogen mensuration) of Mouse Weight (
± S)
Body weight there was no significant difference when by table 12-15 as seen, the initial body weight of mouse, experiment body weight in mid-term and experiment finish between three dosage combinations of the present invention blank group (P〉0.05).Show the present invention on Mouse Weight without impact.
4.2 the present invention is on the impact of mice burden swimming time
Table 16 the present invention on the impact of mice burden swimming time (
± S)
By as seen from Table 16, dosage group and high dose group mice burden swimming time significantly are longer than blank group (P＜0.05) among the present invention.
4.3 the present invention is on the impact of Mouse Blood lactic acid content
Table 17 the present invention on the impact of Mouse Blood lactic acid content (
± S)
By as seen from Table 17, each dosage group of the present invention swim rear three time point blood lactic acid TG-AUCs and blank group there was no significant difference (P〉0.05).
4.4 the present invention is on the impact of mice serum urea nitrogen content
Table 18 the present invention on the impact of mice serum urea nitrogen content (
± S)
By as seen from Table 18,3 dosage groups of the present invention serum urea nitrogen content significantly is lower than blank group (P＜0.05, P＜0.01).
4.5 the present invention is on the impact of Mouse Liver glycogen content
Table 19 the present invention on the impact of Mouse Liver glycogen content (
± S)
By as seen from Table 19, low dose group hepatic glycogen content of the present invention is significantly higher than blank group (P＜0.05).
5. sum up
The present invention significantly is longer than blank group (P＜0.05) the middle and high dosage group mice burden swimming time; Basic, normal, high three dosage group serum urea nitrogen contents significantly are lower than blank group (P＜0.05, P＜0.01); The low dose group hepatic glycogen content is significantly higher than blank group (P＜0.05).Can judge according to " health food check and assessment technique standard " version in 2003, the present invention has the function of alleviating physical fatigue.
Claims (4)
1. one kind has the health food that improves immunity, antifatigue effect, it is characterized in that, is comprised of the component of following percentage by weight: 20 ~ 40% the Radix Astragali, 20 ~ 40% glutinous rehmannia, 5 ~ 25% the red sage root, 5 ~ 20% the fruit of Chinese wolfberry and 5 ~ 15% Cordyceps sinensis.
2. the health food with raising immunity, antifatigue effect according to claim 1 is characterized in that, described Cordyceps sinensis is natural cordyceps, paecilomycerol bat moth mycelium or Hirsutella sinensis mycelium.
3. the health food with raising immunity, antifatigue effect according to claim 1 and 2 is characterized in that, the formulation of described health food is capsule, pulvis, soft capsule, tablet or oral liquid.
4. the described arbitrary method with the health food that improves immunity, antifatigue effect of preparation claim 1 ~ 3 is characterized in that, may further comprise the steps:
(1) measures each raw material by prescription, pulverize, cross 80 mesh sieves;
(2) each raw material after will sieving mixes, and is prepared into capsule, pulvis, soft capsule or tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012103797045A CN102860509A (en) | 2012-10-09 | 2012-10-09 | Anti-fatigue immunity-improving health food and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012103797045A CN102860509A (en) | 2012-10-09 | 2012-10-09 | Anti-fatigue immunity-improving health food and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102860509A true CN102860509A (en) | 2013-01-09 |
Family
ID=47439861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012103797045A Pending CN102860509A (en) | 2012-10-09 | 2012-10-09 | Anti-fatigue immunity-improving health food and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102860509A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103211220A (en) * | 2013-04-25 | 2013-07-24 | 福建永生活力生物工程有限公司 | Health food with function of enhancing immunity and preparation method thereof |
| CN104273527A (en) * | 2014-08-01 | 2015-01-14 | 东莞市亚洲制药有限公司 | Health composition and preparation method and application of health composition |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1083725C (en) * | 1999-12-30 | 2002-05-01 | 上海华晨生物技术研究所 | Cordyceps medicinal composition and its preparing method |
| CN100998851A (en) * | 2006-12-31 | 2007-07-18 | 蔡绪旺 | Chinese medicinal preparation for curriculum of physical and fatigue reducing |
| CN101322774A (en) * | 2008-03-25 | 2008-12-17 | 深圳力瑞医药科技有限公司 | Medicament composition with fatigue-resisting function and preparation method and application thereof |
| CN101884783A (en) * | 2010-07-08 | 2010-11-17 | 辽宁大学 | Anti-fatigue traditional Chinese medicine containing wheat bran polypeptide and preparation method thereof |
-
2012
- 2012-10-09 CN CN2012103797045A patent/CN102860509A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1083725C (en) * | 1999-12-30 | 2002-05-01 | 上海华晨生物技术研究所 | Cordyceps medicinal composition and its preparing method |
| CN100998851A (en) * | 2006-12-31 | 2007-07-18 | 蔡绪旺 | Chinese medicinal preparation for curriculum of physical and fatigue reducing |
| CN101322774A (en) * | 2008-03-25 | 2008-12-17 | 深圳力瑞医药科技有限公司 | Medicament composition with fatigue-resisting function and preparation method and application thereof |
| CN101884783A (en) * | 2010-07-08 | 2010-11-17 | 辽宁大学 | Anti-fatigue traditional Chinese medicine containing wheat bran polypeptide and preparation method thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103211220A (en) * | 2013-04-25 | 2013-07-24 | 福建永生活力生物工程有限公司 | Health food with function of enhancing immunity and preparation method thereof |
| CN104273527A (en) * | 2014-08-01 | 2015-01-14 | 东莞市亚洲制药有限公司 | Health composition and preparation method and application of health composition |
| CN104273527B (en) * | 2014-08-01 | 2017-12-05 | 东莞市亚洲制药有限公司 | A kind of health composition and its production and use |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103169079A (en) | Health-care food with anti-fatigue and immunity-enhancing effects, and preparation method thereof | |
| CN103800390B (en) | Health-care product with immunity-reinforcing and liver-protecting functions, preparation method and application thereof | |
| CN105310075A (en) | Preparation method of natto red yeast rice health care food for assisting in lowering blood lipid | |
| CN101856120A (en) | Health food for improving immunity of human body and preparation method thereof | |
| CN109123612A (en) | A kind of composition with strengthen immunity, health food and preparation method thereof | |
| CN103829234A (en) | Health food capable of improving immunity and reducing blood fat and preparation method thereof | |
| CN103169737B (en) | Composite of Antrodia camphorata entity and shell-broken ganoderma lucidum spore powder and application thereof in immune adjustment | |
| CN102960715A (en) | Immunity-enhancing and hypoxia tolerant health food and preparation method thereof | |
| CN103584091B (en) | A kind of guarantor with raising immunity, hypolipemic function builds food and preparation method thereof | |
| CN102871120A (en) | Heath-care food for improving human immunity and preparation method thereof | |
| CN102429150A (en) | Vitamin C chewable tablet for enhancing human immunity | |
| CN102860496B (en) | Oxidation-resisting health-care food for improving immunity and preparation method thereof | |
| CN102860510A (en) | Anti-fatigue anti-anoxia health food and preparation method thereof | |
| CN102754833B (en) | Healthcare product with function of enhancing immunity and preparation method thereof | |
| CN102860509A (en) | Anti-fatigue immunity-improving health food and preparation method thereof | |
| CN102860495B (en) | Anti-anoxia immunity-improving health food and preparation method thereof | |
| CN103520318A (en) | Traditional Chinese medicine composition of enhancing immune function and preparation method of composition | |
| CN106377541A (en) | Polysaccharide composition and application thereof | |
| CN103039977A (en) | Healthcare food with functions of immunity improvement and hypoxia tolerance and preparation method thereof | |
| CN102987203A (en) | Immunity-improving and blood fat-reducing health food and preparation method thereof | |
| CN104189038B (en) | Chinese medicine preparation for nursing one's health female pathology health and immunologic function | |
| CN107951992A (en) | A kind of Chinese medicine composition for strengthen immunity and preparation method thereof | |
| CN108057049A (en) | A kind of Chinese medicine composition for enhancing cell viability and preparation method thereof | |
| CN102860508A (en) | Immunity-enhancing and anti-fatigue health-care food and preparation method thereof | |
| CN103082286B (en) | Health-care food for enhancing immunity and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: S + P PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: S+P PHARMACEUTICAL CO., LTD. Effective date: 20130916 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20130916 Address after: 810007 Qinghai province Xining City Chengdong District No. 58 Delingha Road Applicant after: S&P Pharma Co., Ltd. Address before: 810007 Qinghai province Xining City Chengdong District No. 58 Delingha Road Applicant before: S & P Pharmaceutical Co.,Ltd. |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130109 |